ES2347979T3 - Supresion de la apoptosis en linfocitos b en animales transgenicos que expresan inmunoglobulina humanizada. - Google Patents

Supresion de la apoptosis en linfocitos b en animales transgenicos que expresan inmunoglobulina humanizada. Download PDF

Info

Publication number
ES2347979T3
ES2347979T3 ES06789294T ES06789294T ES2347979T3 ES 2347979 T3 ES2347979 T3 ES 2347979T3 ES 06789294 T ES06789294 T ES 06789294T ES 06789294 T ES06789294 T ES 06789294T ES 2347979 T3 ES2347979 T3 ES 2347979T3
Authority
ES
Spain
Prior art keywords
immunoglobulin
transgenic
human
expression
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06789294T
Other languages
English (en)
Spanish (es)
Inventor
Josef Platzer
Roland Buelow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapeutic Human Polyclonals Inc
Original Assignee
Therapeutic Human Polyclonals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Human Polyclonals Inc filed Critical Therapeutic Human Polyclonals Inc
Application granted granted Critical
Publication of ES2347979T3 publication Critical patent/ES2347979T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES06789294T 2005-08-03 2006-08-02 Supresion de la apoptosis en linfocitos b en animales transgenicos que expresan inmunoglobulina humanizada. Active ES2347979T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70530505P 2005-08-03 2005-08-03
US705305P 2005-08-03

Publications (1)

Publication Number Publication Date
ES2347979T3 true ES2347979T3 (es) 2010-11-26

Family

ID=37309396

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06789294T Active ES2347979T3 (es) 2005-08-03 2006-08-02 Supresion de la apoptosis en linfocitos b en animales transgenicos que expresan inmunoglobulina humanizada.

Country Status (9)

Country Link
US (3) US7919672B2 (enExample)
EP (1) EP1910418B1 (enExample)
JP (1) JP5188969B2 (enExample)
CN (3) CN102443058A (enExample)
AT (1) ATE474853T1 (enExample)
CA (1) CA2616069C (enExample)
DE (1) DE602006015653D1 (enExample)
ES (1) ES2347979T3 (enExample)
WO (1) WO2007019223A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027986A2 (en) 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
US20080227688A1 (en) * 2007-03-13 2008-09-18 Johnston Randal N Inhibition of viral replication
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
CA3133545C (en) * 2012-05-25 2023-08-08 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
EP4141108A1 (en) 2013-12-24 2023-03-01 Kling Biotherapeutics B.V. Ex vivo antibody production
WO2015143284A1 (en) * 2014-03-21 2015-09-24 The General Hospital Corporation Essential fatty acid-producing nonhuman transgenic animals and uses thereof
IL297997A (en) * 2015-03-04 2023-01-01 Igm Biosciences Inc Cd20 binding molecules and uses thereof
EP4335918A3 (en) * 2015-04-03 2024-04-17 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
IL263160B2 (en) * 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
CN110373428A (zh) * 2016-10-08 2019-10-25 杭州电子科技大学 一种促进细胞移植和基因表达的转基因载体系统及其应用
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
JP2021508471A (ja) 2017-12-29 2021-03-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｖｅｇｆ抗体のｖｅｇｆ受容体遮断選択性を改善する方法
CN111349615B (zh) * 2018-12-24 2024-08-13 上海细胞治疗集团股份有限公司 制备过表达外源基因的细胞的方法
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2509700A (en) * 1999-01-25 2000-08-07 E.I. Du Pont De Nemours And Company Polysaccharide fibers
CA2634294A1 (en) * 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
WO2004037849A2 (en) * 2002-10-21 2004-05-06 Regents Of The University Of Minnesota Transgenic non-human animals with expanded mature b cell and plasma cell populations

Also Published As

Publication number Publication date
EP1910418A1 (en) 2008-04-16
CN102443058A (zh) 2012-05-09
JP5188969B2 (ja) 2013-04-24
US20070033661A1 (en) 2007-02-08
US20110219465A1 (en) 2011-09-08
CN103710371A (zh) 2014-04-09
US20130102072A1 (en) 2013-04-25
CN101263158B (zh) 2011-12-28
US7919672B2 (en) 2011-04-05
ATE474853T1 (de) 2010-08-15
CN103710371B (zh) 2017-03-01
WO2007019223A1 (en) 2007-02-15
EP1910418B1 (en) 2010-07-21
CN101263158A (zh) 2008-09-10
CA2616069C (en) 2018-07-31
DE602006015653D1 (de) 2010-09-02
CA2616069A1 (en) 2007-02-15
US8354568B2 (en) 2013-01-15
JP2009502203A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
US8354568B2 (en) Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin
US11230697B2 (en) Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
ES2473596T3 (es) Loci de inmunoglobulina humanizada
US20080184380A1 (en) Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
KR20110020860A (ko) 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
US10370641B2 (en) Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
US20040158880A1 (en) Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies